Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Basilea Asahi Kasei Cresemba Pediatric Japan Study

Analysis based on 6 articles · First reported Sep 14, 2026 · Last updated Sep 14, 2026

Sentiment
8
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The news is a modest positive for Basilea as it expands the potential pediatric label for its largest product, Cresemba, in Japan, though the financial effect is limited until approval and launch. Market reaction was muted, with Basilea shares slightly lower on the day despite touching a 52-week intraday high.

pharmaceuticals biotechnology

Basilea Pharmaceutica announced that its Japanese partner Asahi Kasei started a Phase 2 clinical study of the antifungal Cresemba (isavuconazole) in Japan for pediatric patients at risk of deep mycoses. The multicenter, open-label, non-controlled study will assess the safety and pharmacokinetics of Cresemba in children. Cresemba is already approved for pediatric use in the United States, Canada, Europe and China, but in Japan it is currently approved only for adults with severe fungal infections. Basilea noted that global in-market sales of Cresemba reached USD 782 million in the twelve months from April 2025 to March 2026, up 27 percent year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide. Basilea also said its Phase 3 program for antifungal Fosmanogepix remains on track for a 2028 data readout and regulatory submission, and that it is preparing Phase 3 development of antibiotic ceftibuten-ledaborbactam while advancing earlier-stage programs. As of June 30, 2026, Basilea held cash, cash equivalents and restricted cash of CHF 175.98 million. Basilea shares reached a 52-week high of CHF 68.00 in intraday trading on Monday and were trading at CHF 66.40, down 0.45 percent on the SIX Swiss Exchange.

90 Asahi Kasei started phase 2 study
60 Basilea Pharmaceutica announced study start
40 Basilea Pharmaceutica reported Cresemba sales
35 Basilea Pharmaceutica reached 52-week high
20 Basilea Pharmaceutica held cash reserves
stock
Basilea is the originator of Cresemba and the main beneficiary of the pediatric study start in Japan, which could broaden the drug's label and future sales. The company also highlighted its broader anti-infective pipeline and a solid cash position of CHF 175.98 million.
Importance 95.0 Sentiment 15.0
stock
Asahi Kasei, through its therapeutics unit, is Basilea's Japanese partner and is conducting the Phase 2 pediatric study, strengthening its role in the Japanese antifungal market.
Importance 80.0 Sentiment 8.0
cnt
Japan is the country where the Phase 2 pediatric study is being conducted and where Cresemba is currently approved only for adults, making it the key target market for the potential label expansion.
Importance 60.0 Sentiment 5.0
exch
The exchange is where Basilea shares trade; the stock reached a 52-week intraday high of CHF 68.00 before easing 0.45 percent to CHF 66.40.
Importance 20.0 Sentiment 0.0
cnt
Switzerland is Basilea's headquarters location and home market, with the company listed on the SIX Swiss Exchange.
Importance 15.0 Sentiment 0.0
curr
The Switzerland — Swiss franc is Basilea's reporting currency context, with the company holding CHF 175.98 million in cash and its shares priced in francs.
Importance 15.0 Sentiment 0.0
cnt
The United States is one of the markets where Cresemba is already approved for pediatric use, providing precedent for the Japanese study.
Importance 10.0 Sentiment 0.0
curr
The US dollar is the currency in which Cresemba's global in-market sales of USD 782 million were reported.
Importance 10.0 Sentiment 0.0
cnt
The United Kingdom is among the markets where Cresemba is already approved for pediatric patients.
Importance 5.0 Sentiment 0.0
cnt
Canada is among the markets where Cresemba is already approved for pediatric patients.
Importance 5.0 Sentiment 0.0
cnt
China is among the markets where Cresemba is already approved for pediatric patients.
Importance 5.0 Sentiment 0.0
alliance
The European Union is among the markets where Cresemba is already approved for pediatric patients.
Importance 5.0 Sentiment 0.0
stock
Astellas is referenced as the source of the US prescribing information for Cresemba, indicating its role in the product's US commercialization.
Importance 5.0 Sentiment 0.0
Japan related ↔ Switzerland
Japan ally ↔ United States Japan views the United States as its indispensable security guarantor and a crucial economic partner, with deep investme
Japan related ↔ United Kingdom
Japan related ↔ Canada
Switzerland related ↔ Canada
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
United States trade rivals ↔ Canada The United States views Canada as a key defense partner but also a trade rival, having imposed tariffs and declined to r
United Kingdom related ↔ Canada
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.